Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score Test in Patients Regardless of Age or Race

Learn more about SABCS

See What We Presented

TAILORx Age <50

Prognostic impact of the 21-gene Recurrence Score assay among young women with node-negative and node-positive ER+/HER2- breast cancer

Poorvu P, et al.

Download the poster

SEER TAILORx Node-positive

Breast Cancer-specific Mortality in Patients With Node-negative and Node-positive Breast Cancer Guided by the 21-gene Assay: A SEER-Genomic Population-based Study.

Hortobagyi G, et al.

Download the poster

The New Breast Recurrence Score Report

The newly designed Breast Recurrence Score test report for your ER+, HER2-, early-stage breast cancer patients provides 3 points of clarity to aid in treatment decisions

See the new report
*NCCN and NCCN Guidelines are trademarks of the National Comprehensive Cancer Network. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed [October 5, 2018]. To view the most recent and complete version of the guideline, go to NCCN does not endorse any product or therapy.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™